Skip Ribbon Commands
Skip to main content
Menu
Dr Chandramouli Nagarajan

Dr Chandramouli Nagarajan

MBBS, FRCP(Edin), FRCPath(UK)

Senior Consultant

Singapore General Hospital

Specialty: Haematology, Haematology

Sub-specialties: Lymphoma, Myeloma

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Aplastic Anaemia, Chronic lymphocytic leukemia, Chronic Myeloid Leukemia (CML), Deep Vein Thrombosis, Deep Vein Thrombosis, essential thrombocythemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelofibrosis, Polycythemia Vera, Thalassaemia.

Clinical Appointments

  • Myeloma Services Singapore General HospitalSingapore General Hospital
  • Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Senior Consultant SingHealth Duke-NUS Transplant Centre
  • Senior Consultant Haematology Singapore General HospitalSingapore General Hospital

Profile

Dr. Chandramouli completed his undergraduate training from South India followed by a 3-year Internal Medicine Residency MD programme at the prestigious Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. He continued his medical and haematology training in the UK, where he completed his FRCPath and received the Certificate of completion of specialist training (CCT). He served as a Consultant Haematologist at Warrington & Halton Hospitals NHS Foundation trust for 2 1/2 years, before moving to Singapore.

He also holds academic position as Senior Lecturer, Yong Loo Lin School of Medicine and Clinical Assistant Professor in DUKE-NUS Medical School.

His main areas of focus are management of lymphoproliferative disorders including myeloma, lymphoma and laboratory haematology. He is the Lead of the Lymphoma and Myeloma Services at SGH and is actively involved as a principal investigator of clinical trials in lymphoproliferative disorders especially myeloma focusing on novel agents, small molecules, and immunotherapy. His other area of interest is medical education and currently serves as the Program Director for SingHealth Haematology Senior Residency Program.

Education

  • ​FRCP (Edin) 
  • FRCPath Haematology UK
  • MRCP (UK)
  • MD (Internal Medicine)
  • MBBS 

Professional Appointments and Committee Memberships

  • Clinical Senior Lecturer, Yong Loo Lin School of Medicine
  • Clinical Assistant Professor, Duke-NUS Medical School.
  • Residency Programme Director, National and SingHealth Haematology Residency Program
  • Director of Education, SingHealth Duke-NUS Blood Cancer Center
  • Campus Service Chief, SingHealth-Duke NUS Cellular Therapy Center
  • Implementation Office, ACTRIS

Awards

  • EHA Clinical Research Training in Haematology Scholarship Award
  • Outstanding Residency Faculty Award
  • Service with a Heart Award
  • Singapore Health Quality Service Award

Research Interests

Publications

  • Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, et al. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. Vol. 20, Molecular Cancer. 2021. p. 134.
  • Chen Y, Nagarajan C, Tan MS, Martinelli G, Cerchione C. BCMA-targeting approaches for treatment of multiple myeloma. Panminerva Med [Internet]. 2021 Mar;63(1):28–36. 
  • Lee LH, Nagarajan C, Tan CW, Ng HJ. Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review. Front Cardiovasc Med. 2021;8(May).
  • Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J [Internet]. 2021 Aug 12;11(8):143. 
  • Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Vol. 11, Blood cancer journal. 2021. p. 150.
  • Ong SY, Lim JQ, Grigoropoulos N, Laurensia Y, Huang D, Chia BKH, et al. No association between ECSIT germline mutations and hemophagocytic  lymphohistiocytosis in natural killer/T-cell lymphoma. Vol. 106, Haematologica. 2021. p. 1737–9.
  • Nagarajan C, Tan MS, Chen Y, Martinelli G, Cerchione C. Current and future perspectives of maintenance therapy in multiple myeloma. Panminerva Med [Internet]. 2020 Dec;62(4):225–33. 
  • Yeoh K-W, Thitsar SM, Master Z, Loh Y, Chen Y, Nagarajan C, et al. Pleural plasmacytomas - the role of radiotherapy. Vol. 190, British journal of haematology. England; 2020. p. e160–2. 
  • Wang C, Soekojo CY, Mel S de, Ooi M, Chen Y, Goh AZK, et al. Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. Cancers (Basel). 2020 Jul;12(7). 
  • Tan CW, Ho LP, Kalimuddin S, Cherng BPZ, Teh YE, Thien SY, et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B(12) in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition. 2020;79–80:111017.
  • Ong SY, Phipps C, Nagarajan C, Tang T, Lim ST, Goh YT, et al. Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 225–7.
  • Lim CC, Lwin KZL, Cheong MA, Kanagasabapathy K, Nagarajan C, Loh A. An unusual cause of renal tubular dysfunction in multiple myeloma. Vol. 52, International urology and nephrology. Netherlands; 2020. p. 1603–5. 
  • Pwint K-SW, Chen Y, Diong CP, Goh Y-T, Grant D, Ho A, et al. Mobilization kinetics of peripheral blood stem cells with rescue plerixafor - real-world experience from a single center. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 1740–3.
  • Chew AHY, Chandramouli N, Kanesvaran R, Iyer GN, Hwang WYK. Winning the Fight Against Cancer. Ann Acad Med Singapore. 2020 Oct;49(10):779–88.
  • Abdul-Hamil NA, Wong GC, Nagarajan C, Martinelli G, Cherchione C. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. Minerva Med. 2020 Oct;111(5):443–54. 
  • Soekojo CY, Wang G-M, Chen Y, Casan J, Wolyncewicz G, Lin A, et al. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e470–7. 
  • Soekojo CY, Kim K, Huang S-Y, Chim C-S, Takezako N, Asaoku H, et al. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. Blood Cancer J. 2019 Oct;9(10):83.
  • Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, et al. The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 Oct;59(10):2336–41. 
  • Ong SY, Li S-T, Wong GC, Ho AYL, Nagarajan C, Ngeow J. Delayed diagnosis of Shwachman diamond syndrome with short telomeres and a review of cases in Asia. Vol. 9, Leukemia research reports. 2018. p. 54–7. 
  • de Mel S, Chen Y, Gopalakrishnan SK, Ooi M, Teo C, Tan D, et al. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Med J. 2017 Feb;58(2):55–71. 
  • Nagarajan C, Barbieri A, Mittal S. Circulating tumour cells in disseminated malignant melanoma. Br J Haematol. 2012 Mar;156(6):692. 
  • Russo A, Chandramouli N, Zhang L, Deng H. Reductive glutaraldehydation of amine groups for identification of protein N-termini. J Proteome Res. 2008 Sep;7(9):4178–82. 
  • Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004 Jan;64(2):689–95. 
  • Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, et al. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem. 2003 Oct;46(21):4609–24. 
  • Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun;46(12):2334–44. 

Research Trials